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hither Withering’s Legacy?
igoxin’s Role in Our Contemporary
harmacopeia for Heart Failure*
ames B. Young, MD, FACC†
leveland, Ohio
“The use of the Foxglove is getting abroad, and it is better the
world should derive some instruction, however imperfect,
from my experience, than the lives of men should be hazarded
by its unguarded exhibition, or that a medicine of so much
efficacy should be condemned and rejected as dangerous and
unmanageable.”
William Withering, 1785 (1)
“In bringing forward a subject so debated as digitalis and its
action, the only apology the writer can offer is that for years he
has studied effects clinically . . . He has tried to bring to the
inquiry a mind free from prejudice on either side, and impressed
with the wish to elicit the truth.”
J. Milner Fothergill, 1871 (2)
“The Digoxin Investigation Group trial changes one fundamen-
tal aspect of the treatment of heart failure: digoxin’s inability to
substantially influence morbidity and mortality eliminates any
ethical mandate for its use . . .”
Milton Packer, 1998 (3)
“Digitalis is part of the first-line therapy for patients with
clinical heart failure and left ventricular dysfunction.”
Shahbudin H. Rahimtoola, 2005 (4)
See page 497
t is unlikely that any other therapeutic tack in medicine has
een debated as much, as long, or with as great intensity and
nmity as the prescription of digitalis glycosides for the
reatment of dropsical heart failure (1–4). The two-century-
ld debate will likely never completely end because more
ophisticated, evidence-based consensus are unlikely to
ppear. However, we may be closer to the end than ever
efore, if for no other reason than because we may tire of the
ebate (3). It is unlikely that a large, properly powered and
ontrolled, morbidity-mortality end point clinical trial will
ver again be performed with a digitalis preparation in
hronic heart failure. Thus, in this issue of the Journal,
dams et al. (5) offer a statistically elegant re-analysis of the
igitalis Investigation Group (DIG) trial. Two previous
IG trial database analyses by Rathore et al. (6) and a
*Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.M
From †The Kaufman Center for Heart Failure, Cleveland Clinic Foundation, and
erner College of Medicine of Case Western Reserve University, Cleveland, Ohio.ecent re-analysis of the Studies Of Left Ventricular Dys-
unction (SOLVD) trial by Domanski et al. (7) help to put
ome important questions to rest, albeit a fitful one.
Withering had no real insight into the pharmacologic and
hysiologic effects of foxglove tea. Indeed, he could not link
recisely the condition of dropsy to congestive heart failure,
r even the heart per se, although he came tantalizingly
lose. For many years the clinical effects of digoxin, partic-
larly in patients with normal sinus rhythm, were thought to
e related to the inhibition of sodium, potassium, and
denosine triphosphatase interaction, which translated into
ncreased cardiac contractility. More recently, it has been
uggested that the putative benefits of digoxin relate more to
eurohormone modulation, including sensitization of arte-
ial and cardiac baroreceptors, vagolytic-induced decreased
ympathetic nervous system tracking, and suppression of
enal renin secretion (8,9). Whatever the most important
harmacologic and physiologic actions of digoxin may be,
enefits have been suggested in several small, short-term
ollow-up, clinical trials (8–10) and two larger, but non-
orbidity end point “digoxin-withdrawal” studies (11,12).
n aggregate, the benefits seem primarily related to im-
rovement in symptoms and exercise or functional capacity.
The beauty of the DIG trial was, unlike smaller studies,
ts power to address more definitively the question of major
orbidity (hospitalizations, in particular) and mortality.
he DIG trial, which provided substrate for the analysis by
dams et al. (5), was a 6,800-patient randomized, double-
lind, placebo-controlled clinical study of digoxin added to
iuretics and angiotensin-converting enzyme inhibitors in
atients generally with left ventricular ejection fraction
45% (13). A stratification for ejection fraction 45%
llowed patients into the trial with symptomatic congestive
eart failure and more preserved systolic function. During a
hree-year follow-up period, there were no statistically signif-
cant mortality differences between the treatment and con-
rol groups. However, the clinically important end points of
ospitalization for worsening heart failure and all-cause
ospitalizations were significantly diminished. A systemic
eview and meta-analysis of several clinical trials also sug-
ested that digoxin reduces hospitalization rates while
mproving symptoms related to chronic heart failure (14).
Problematic with the DIG trial observations, however,
ave been retrospective database subset analyses suggesting
hat digoxin was associated with adverse events. One anal-
sis suggested that digoxin actually reduced deaths related to
orsening heart failure while, arguably, increasing events
elated to problematic arrhythmias (14). These observations
ed to an underwhelming response from the clinical com-
unity (3). Indeed, more contemporary trial data suggest
hat the use of digoxin has decreased. For example, in the
OLVD “treatment” trial published in 1991 (15), 67% of
articipants were on digoxin compared with 53% in the
andesartan in Heart failure: Assessment of Reduction in
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Editorial Comment August 2, 2005:505–7ublished in 2004 (16). Although conducted more than one
ecade apart, these two studies were very similar in design
haracteristics. Observations perhaps linked to the DIG
rial include the subsequent analysis of the trial dataset, and
he overwhelming evidence that other drugs (beta-blockers,
n particular) clearly reduced heart failure mortality, al-
hough fortunes of this drug have waned.
One DIG trial analysis raised specific concerns about the
se of digoxin in women (17). There was a 5.8% difference
etween men and women with respect to all-cause mortal-
ty. More specifically, the mortality rate in women assigned
o digoxin was 33.1% versus 28.9% in the placebo group,
hereas the rates in men were 35.2% and 36.9%, respec-
ively. A significant interaction analysis existed between
en and women (p  0.034) and, in the multivariable
nalysis, digoxin seemed to be associated with a higher risk
f death in women (hazard ratio 1.23, 95% confidence
nterval 1.02 to 1.47). This analysis is weakened by several
actors, including its post-hoc retrospective subgroup nature
nd an imbalance in important clinical characteristics be-
ween the treatment groups that became apparent during
he trial. Indeed, at the one-month follow-up mark, the
igoxin concentrations were significantly higher in women
han men, and an adjustment was not made for this in the
nalysis of mortality (18). Higher digoxin levels become
xceedingly important. Indeed, overall, “suspected digoxin
oxicity” was noted in 11.9% of the digoxin cohort versus
.9% for placebo, and this difference resulted in 2.0% of the
igoxin and 0.9% of the placebo group being hospitalized.
s Rahimtoola has pointed out, serum digoxin concentra-
ions were 2.0 ng/ml (clearly a toxic level) in 2% of the
igoxin group, and 5% of this cohort had levels in the 1.5-
o 2.0-ng/ml range (a range previously thought reasonable
ut now believed also to be too high) (4,8). When stratified
or gender, 2.3% of men versus 3.4% of women had levels at
he 1-month point 2.0 ng/ml (17). Indeed, in a later
nalysis by Rathore et al. (6), this concept was extended, at
east for the male DIG trial cohort. This analysis demon-
trated an increased mortality rate when digoxin levels were
0.9 ng/ml and suggested benefit (at least in men) when
evels are in the 0.5- to 0.8-ng/ml range.
Put simply, digoxin “toxicity” seems to be the problem.
ndeed, concentrations previously thought reasonable (as
uch as 2.0 ng/ml) are likely excessive. One must remember
hat the dosing scheme in the DIG trial would be consid-
red aggressive by some today. The initial dosage of the
tudy drug was determined by a somewhat-complex nomo-
ram based on age, gender, weight, and serum creatinine.
he goal was, of course, to achieve “therapeutic” and
on-toxic digoxin levels, but what this target should have
een was unclear, as now seems the case. In fact, it was not
ntil these post-hoc analyses of the DIG trial database that
radically lower dose and serum concentration of digoxin
as felt appropriate. Further support of this “low” dose and
erum level concept comes from an analysis (also retrospec-
ive) of the combined Prospective Randomized Study of aentricular Function and Efficacy of Digoxin (PROVED)
nd Randomized Assessment of Digoxin and Inhibitors of
ngiotensin-Converting Enzyme (RADIANCE) database,
hich suggested that low doses of digoxin producing serum
oncentrations of 0.9 to 1.2 ng/ml resulted in clinical benefit
ompared with control patients not receiving the drug (19).
s in the DIG trial, even patients with levels 0.9 ng/ml
id better than those receiving placebo. Also, a dose-
esponse pattern with increasing serum concentrations of
igoxin could not be identified. Today, prescribing low
oses of digoxin to achieve lower serum concentrations is
he best approach for patients with congestive heart failure.
The admirable analysis done by Adams et al. (5) closes,
hen, the DIG trial questions initially raised by the Krum-
olz team in 2002 and then further studied in men in 2003
6,17). The Adams et al. (5) multivariable analysis focused
n patients having serum concentrations of digoxin mea-
ured 6 to 30 h after the last dose of study drug at 4 weeks
nd also demonstrated a significant linear relationship
etween serum digoxin concentration and mortality in
omen (p  0.008) as well as in men (p  0.002) with no
ender interaction (p  0.766). The compendium of infor-
ation demonstrates satisfactorily that the issue is not
ender but, rather, the dose of digoxin and resulting serum
oncentrations. Overall, there appears to be morbidity
eduction in both men and women taking digoxin when the
erum concentrations are 0.5 to 0.9 ng/ml, whereas serum
oncentrations greater than this appear harmful irrespective
f gender. It is, then, comforting to note that in the earlier
OLVD trial, an analysis of the interaction between gender
nd digoxin treatment on mortality also suggested no
ifference in survival between men and women based on
igoxin use (7).
In the end, whither digoxin? Certainly it seems not the
ithering of this therapy. The compendium of evidence
uggests that, as does the last American College of Cardi-
logy/American Heart Association (ACC/AHA) Guide-
ines for Chronic Heart Failure, digoxin should still be
rescribed for the treatment of heart failure symptoms
nless contraindicated. This important strategy ameliorates
ymptoms and prevents hospitalizations for decompensated
eart failure rather than affecting mortality reduction (19–
1). These end points are important and compelling. This
ecommendation from the ACC/AHA is based on multiple
linical trial observations and general agreement that the
herapy is useful and effective, earning it a class IA endorse-
ent. In view of the more recent insight gained into the use
f digoxin in heart failure, it is hoped that this particular
ecommendation remains intact as the Guideline is updated.
lso important is the fact that the vast majority of contem-
orary clinical trials in heart failure cohorts add study
nterventions to baseline therapies usually comprising the
igoxin, angiotensin-converting enzyme inhibitor, and
eta-blocker troika. As well, we now have reassuring data
ndicating lower doses and serum concentrations of digoxin
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August 2, 2005:505–7 Editorial Commenterum concentrations0.9 ng/ml appear the optimal target.
ranted, therapy of heart failure remains difficult, and
uilding polypharmacy protocols can be problematic. None-
heless, digoxin should still be an important and often, but
ppropriately, prescribed heart failure treatment. Long live
ithering’s legacy!
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